Here, we evaluated the relationship between MSLN expression and cytotoxic CD8+ T cell infiltration in pancreatic cancer, and investigated the feasibility and safety of combing personalized neoantigen vaccine with anti‐MSLN antibody to improve the immunotherapy efficacy of pancreatic cancer in subcutaneous and orthotopic mouse models. The gene discussed is CD8A; the disease is pancreatic neoplasm.